Registered number
00620867
DHP Healthcare Limited
Filleted Accounts
31 December 2024
DHP Healthcare Limited
Registered number: 00620867
Balance Sheet
as at 31 December 2024
Notes 2024 2023
£ £
Fixed assets
Intangible assets 3 96,359 24,558
Current assets
Stocks 107,616 37,253
Debtors 4 120,903 38,094
Cash at bank and in hand 214,787 46,229
443,306 121,576
Creditors: amounts falling due within one year 5 (433,259) (81,479)
Net current assets 10,047 40,097
Net assets 106,406 64,655
Capital and reserves
Called up share capital 466,025 211,025
Profit and loss account (359,619) (146,370)
Shareholders' funds 106,406 64,655
The directors are satisfied that the company is entitled to exemption from the requirement to obtain an audit under section 477 of the Companies Act 2006.
The members have not required the company to obtain an audit in accordance with section 476 of the Act.
The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of accounts.
The accounts have been prepared and delivered in accordance with the special provisions applicable to companies subject to the small companies regime. The profit and loss account has not been delivered to the Registrar of Companies.
Mr R Garella Mr R P Dhorajiwala
Director Director
Approved by the board on 8 July 2025
DHP Healthcare Limited
Notes to the Accounts
for the year ended 31 December 2024
1 Accounting policies
Basis of preparation
The accounts have been prepared under the historical cost convention and in accordance with FRS 102, The Financial Reporting Standard applicable in the UK and Republic of Ireland (as applied to small entities by section 1A of the standard).
Turnover
Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services. Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have transferred to the buyer.
Product development expenditure
Capital expenditure on research and development (R & D) is capitalised as intangible fixed assets. Development cost relating to the new and improved product and/or process development is recognised as an intangible asset to the extent that such asset will generate future economical benefits. Other research and development cost is expensed as incurred.

Product development expenditure is reviewed for impairment annually or whenever events or changes in circumstances indicate that the carrying value may not be recoverable.

Product development costs are amortised over the useful life, not exceeding 10 years, once the product to which they relate is commercialised.
Stocks
Stocks are measured at the lower of cost and estimated selling price less costs to complete and sell. Cost is determined using the first in first out method. The carrying amount of stock sold is recognised as an expense in the period in which the related revenue is recognised.
Debtors
Short term debtors are measured at transaction price (which is usually the invoice price), less any impairment losses for bad and doubtful debts. Loans and other financial assets are initially recognised at transaction price including any transaction costs and subsequently measured at amortised cost determined using the effective interest method, less any impairment losses for bad and doubtful debts.
Creditors
Short term creditors are measured at transaction price (which is usually the invoice price). Loans and other financial liabilities are initially recognised at transaction price net of any transaction costs and subsequently measured at amortised cost determined using the effective interest method.
Taxation
A current tax liability is recognised for the tax payable on the taxable profit of the current and past periods. A current tax asset is recognised in respect of a tax loss that can be carried back to recover tax paid in a previous period. Deferred tax is recognised in respect of all timing differences between the recognition of income and expenses in the financial statements and their inclusion in tax assessments. Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference, except for revalued land and investment property where the tax rate that applies to the sale of the asset is used. Current and deferred tax assets and liabilities are not discounted.
Provisions
Provisions (ie liabilities of uncertain timing or amount) are recognised when there is an obligation at the reporting date as a result of a past event, it is probable that economic benefit will be transferred to settle the obligation and the amount of the obligation can be estimated reliably.
Foreign currency translation
Transactions in foreign currencies are initially recognised at the rate of exchange ruling at the date of the transaction. At the end of each reporting period foreign currency monetary items are translated at the closing rate of exchange. Non-monetary items that are measured at historical cost are translated at the rate ruling at the date of the transaction. All differences are charged to profit or loss.
Going concern
The directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. The company therefore continues to adopt the going concern basis in preparing its financial statements.
Pensions
Contributions to defined contribution plans are expensed in the period to which they relate.
2 Employees 2024 2023
Number Number
Average number of persons employed by the company 2 2
3 Intangible fixed assets £
Product development expenditure
Cost
At 1 January 2024 33,927
Additions 83,527
At 31 December 2024 117,454
Amortisation
At 1 January 2024 9,369
Provided during the year 11,726
At 31 December 2024 21,095
Net book value
At 31 December 2024 96,359
At 31 December 2023 24,558
Product development expenditure is being written off in equal annual instalments over its estimated economic life.
4 Debtors 2024 2023
£ £
Trade debtors 118,568 14,218
Amounts owed by holding company - 12,890
Other debtors 2,335 10,986
120,903 38,094
5 Creditors: amounts falling due within one year 2024 2023
£ £
Trade creditors 139,569 80,479
Amounts owed to holding company 17,502 -
Taxation and social security costs 8,804 -
Other creditors 267,384 1,000
433,259 81,479
6 Related party transactions
Other creditors includes a loan of £168,858 (2023: nil) due to Mr.Terry Coughlin. Mr Terry Coughlin is a director and a shareholder of Wyntra Holdings Limited, the parent company.The loan is for a period of 11 months and interest is payable on the loan at the rate of 12% per annum.

Also inclded in other creditors is a loan of £75,000 (2023: nil) due to Mr Rahul Garella who is a director and a shareholder of the company and the parent company.The loan is for a period of 11 months and and interest is payable on the loan at the rate of 12% per annum.
7 Controlling party
The company is a subsidiary of Wyntra Holdings Limited, a company registered in Republic of Ireland.
8 Other information
DHP Healthcare Limited is a private company limited by shares and incorporated in England. Its registered office is:
13 Hanover Square
London
England
W1S 1HN
DHP Healthcare Limited 00620867 false 2024-01-01 2024-12-31 2024-12-31 VT Final Accounts April 2025 Mr R Garella Mr R P Dhorajiwala No description of principal activity 00620867 2023-01-01 2023-12-31 00620867 core:WithinOneYear 2023-12-31 00620867 core:ShareCapital 2023-12-31 00620867 core:RetainedEarningsAccumulatedLosses 2023-12-31 00620867 2024-01-01 2024-12-31 00620867 bus:PrivateLimitedCompanyLtd 2024-01-01 2024-12-31 00620867 bus:AuditExemptWithAccountantsReport 2024-01-01 2024-12-31 00620867 bus:Director40 2024-01-01 2024-12-31 00620867 1 2024-01-01 2024-12-31 00620867 2 2024-01-01 2024-12-31 00620867 core:Goodwill 2024-01-01 2024-12-31 00620867 countries:England 2024-01-01 2024-12-31 00620867 bus:FRS102 2024-01-01 2024-12-31 00620867 bus:FilletedAccounts 2024-01-01 2024-12-31 00620867 2024-12-31 00620867 core:WithinOneYear 2024-12-31 00620867 core:ShareCapital 2024-12-31 00620867 core:RetainedEarningsAccumulatedLosses 2024-12-31 00620867 core:Goodwill 2024-12-31 00620867 2023-12-31 00620867 core:Goodwill 2023-12-31 iso4217:GBP xbrli:pure